In the Czech Republic, we invest more than 200 million Czech Crowns a year in clinical research. Clinical trials of new drugs are carried out in collaboration with medical doctors at leading healthcare facilities across the Czech Republic.
International research projects in the Czech Republic draw data from more than 70 clinical trials in various phases: from the first administration of the drug to the patient, through the finetuning of the optimal dosage to comparing the new treatment to the already available treatment for the condition in question. Other trials examine the economic benefits of treatment and value for the patient’s life. The focus is on treating cardiovascular, oncological and autoimmune diseases, diabetes, eye conditions and dysfunctions of the central nervous system.
Under the exert guidance of the State Institute for Drug Control (SÚKL) and hospital ethical committees, new Novartis drugs are administered to more than 2,000 patients under strictly controlled conditions.